Kura Oncology (NASDAQ:KURA) has been assigned a $31.00 price objective by stock analysts at HC Wainwright in a research note issued to investors on Thursday. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 182.85% from the stock’s current price.
Several other equities research analysts have also issued reports on the stock. BidaskClub lowered shares of Kura Oncology from a “sell” rating to a “strong sell” rating in a report on Wednesday, October 24th. Cowen restated a “buy” rating on shares of Kura Oncology in a report on Monday, October 22nd. ValuEngine lowered shares of Kura Oncology from a “strong-buy” rating to a “buy” rating in a report on Friday, October 19th. Finally, Zacks Investment Research upgraded shares of Kura Oncology from a “sell” rating to a “buy” rating and set a $18.00 target price for the company in a report on Tuesday, October 16th. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $26.33.
Kura Oncology stock traded up $0.01 during midday trading on Thursday, reaching $10.96. 170,595 shares of the company traded hands, compared to its average volume of 373,111. Kura Oncology has a 12 month low of $10.20 and a 12 month high of $24.02.
Kura Oncology (NASDAQ:KURA) last released its earnings results on Thursday, August 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.45).
A number of hedge funds have recently bought and sold shares of KURA. Wells Fargo & Company MN increased its stake in Kura Oncology by 69.3% in the 1st quarter. Wells Fargo & Company MN now owns 59,448 shares of the company’s stock worth $1,115,000 after buying an additional 24,343 shares during the period. Schwab Charles Investment Management Inc. increased its stake in Kura Oncology by 10.3% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 45,174 shares of the company’s stock worth $848,000 after buying an additional 4,200 shares during the period. Northern Trust Corp increased its stake in Kura Oncology by 8.9% in the 1st quarter. Northern Trust Corp now owns 255,508 shares of the company’s stock worth $4,791,000 after buying an additional 20,961 shares during the period. BlackRock Inc. increased its stake in Kura Oncology by 4.6% in the 1st quarter. BlackRock Inc. now owns 1,595,302 shares of the company’s stock worth $29,910,000 after buying an additional 70,485 shares during the period. Finally, UBS Group AG increased its stake in Kura Oncology by 145.4% in the 1st quarter. UBS Group AG now owns 30,671 shares of the company’s stock worth $575,000 after buying an additional 18,171 shares during the period. 77.28% of the stock is currently owned by institutional investors.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
See Also: Book Value Per Share – BVPS
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.